ASCO 2022 | Systemic triple therapy in metastatic hormone-sensitive prostate cancer

Andrew J. Armstrong, MD, Duke Cancer Center, Durham, NC, comments on novel advances in the management of metastatic hormone-sensitive prostate cancer (mCRPC). Systemic triple therapy in the form of androgen deprivation therapy (ADT) and androgen receptor (AR) antagonists such as abiraterone and darolutamide accompanied with enzalutamide and apalutamide or chemotherapy such as docetaxel has become the new standard of care for patients with de novo metastatic prostate cancer. This interview took place at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL.